Inocras Inc. utilizes whole genome sequencing and a proprietary bioinformatics platform to provide detailed genetic insights for patients with cancer and rare diseases. This technology identifies complex mutations often missed by standard tests, enabling more accurate diagnoses and personalized treatment options.
Funding
$52.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
BMFounders
Product
Problem
Standard genetic panel testing and whole exome sequencing often miss complex mutations, structural variants, and variants in non-coding regions, leaving many cancer and rare disease cases undiagnosed or improperly characterized. This incomplete genetic picture limits the potential for personalized treatment and delays accurate diagnoses.
Solution
Inocras offers whole genome sequencing and a proprietary bioinformatics platform to provide comprehensive genetic insights for patients with cancer and rare diseases. Their technology captures >99% of a patient's genetic makeup, identifying complex mutations often missed by standard tests. The platform translates genomic data into actionable findings, delivered through user-friendly reports that highlight treatment options, genomic instability, and germline analysis. Inocras also connects patients to matching clinical trials and provides genetic counseling support.
Target Audience
Inocras serves patients with cancer and rare diseases, as well as the providers and researchers who support them.
Features
- Target-enhanced whole genome sequencing for solid tumors (CancerVision) with >99% sensitivity and positive predictive value
- Whole genome sequencing for rare disease diagnosis (RareVision), covering genes associated with 5,000+ rare diseases
- Ultra-sensitive, whole-genome tumor-informed ctDNA test for minimal residual disease detection (MRDVision) with a limit of detection as low as 2ppm (LOD95) (research use only)
- Detection of SNVs, indels, CNVs, SVs, and variants in non-coding regions
- Proprietary bioinformatics platform for translating genomic data into actionable insights
- Easy-to-read reports with treatment options, genomic instability, and germline analysis
- Clinical trial matching and genetic counseling support
- CAP/CLIA-certified assays with a 2-week turnaround time